A Phase 1 Study of INCB160058 in People With Myeloproliferative Neoplasms

Full Title

A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms

Purpose

Researchers want to find the best dose of INCB160058 to treat myeloproliferative neoplasms such as myelofibrosis. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change) in the JAK2 gene.

INCB160058 blocks a protein that can cause cancer cells to grow. By blocking this protein, INCB160058 may help slow or stop the growth of your cancer. INCB160058 is taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Raajit Rampal’s office at 646-608-3746.